Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model

European Journal of Pharmaceutics and Biopharmaceutics(2020)10.1016/j.ejpb.2020.11.019Source: DataRank Database

Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model is a research paper published in European Journal of Pharmaceutics and Biopharmaceutics (2020). On theSindex it has a DataRank of 0. It has been cited 77 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access77 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 5.11)OA: greenTopics (39)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Diana H. Quan ORCID,Rachel Yoon Kyung Chang ORCID,Michael Y.T. Chow,Yuncheng Wang ORCID,Mengyu Li ORCID

Live enrichment

PubMed:33253892 PMC:PMC7855557 OpenAlex:https://openalex.org/W3107162773

NIAID NIH HHS

Grant: R33 AI121627

National Institutes of Health

National Health and Medical Research Council

FWCI

5.11

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7855557

publisherhttps://api.elsevier.com/content/article/PII:S0939641120303520?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0939641120303520?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ejpb.2020.11.019

Fields of Study

Bacteriophages and microbial interactionsMicrobial infections and disease researchAntibiotic Resistance in Bacteria

MeSH Terms

Phage TherapyProof of Concept StudyAdministration, InhalationAnimalsAnti-Bacterial AgentsCiprofloxacinCombined Modality TherapyFemaleHumansLungPowdersPseudomonas aeruginosaPseudomonas InfectionsPneumonia, BacterialMiceBacterial LoadDry Powder Inhalers

Keywords

CiprofloxacinPseudomonas aeruginosaMicrobiologyAntibioticsAntimicrobialColony-forming unitIn vivoChemistryPharmacologyBacteriaMedicineBiologyCombination therapyBacteriophage TherapyMouse Lung Infection ModelInhaled Phage TherapyPhage And Antibiotic CombinationAntibiotic AerosolsDry Powder Inhalation (Dpi)